Dapagliflozin: 12 agencies, 2012–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “In adults for the treatment of chronic kidney disease (CKD).”, while PBAC (Australia) recorded not recommended for “Chronic kidney disease”.
Where dapagliflozin met resistance it was usually narrowed rather than refused: 21 of 50 decisive outcomes were recommendations with restrictions, against 6 outright refusals.
CONITEC (Brazil) has been easier on dapagliflozin than on its own caseload: it refused 1 of 5 decisive submissions here (20%), against a base rate of 44% across everything it has assessed.
The file has been open for more than a decade: 13.3 years separate the first record, 14 Aug 2012 at AWMSG (Wales), from the most recent, 29 Dec 2025 at CONITEC (Brazil).
AOTMIT (Poland) changed its position: not recommended on 17 Feb 2021, recommended by 22 Jan 2025, after a resubmission.
No assessment is on file from HAS (France), which is among the eight highest-volume agencies here.
Not every gap is a refusal: for dapagliflozin, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 19 of 64 records date from 2023 or later.
The programme is broad: 16 distinct indication wordings are recorded for dapagliflozin by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
13 of these 64 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess dapagliflozin, on 14 Aug 2012; AIFA (Italy) did not open a file until 20 Feb 2024 — an unusually long tail of 11.5 years between the earliest and latest system to look at it.
The record arrives in waves: 9 separate years each carry two or more decisions, spread across 13 years in total.
Restriction is doing real work here: 21 of 50 decisive outcomes narrowed dapagliflozin to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and NICE (England) among others.
12 of the 12 agencies here assessed dapagliflozin more than once, PBAC (Australia) most often at 13 entries — repeat review is the norm for this molecule rather than the exception.
dapagliflozin has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for dapagliflozin reads 23 recommended, 21 restricted, 6 not recommended and 5 deferred to NICE, with 9 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NICE (England) | 2 Jul 2025 | NICE TA1075 | published appraisal | source |
| PBAC (Australia) | 2025 | Chronic kidney disease (CKD) | Recommended | source |
| SMC (Scotland) | 7 Apr 2025 | In adults for the treatment of chronic kidney disease (CKD). | accepted (restricted) | source |
| AIFA (Italy) | 14 Mar 2025 | EDISTRIDE è indicato negli adulti per il trattamento dell’insufficienza cardiaca cronica sintomatica classe NYHA II-III … | conditionally innovative, since expired | source |
| AOTMIT (Poland) | 17 Feb 2021 | Forxiga reimbursement recommendation | not recommended | source |
59 further decisions for dapagliflozin, across 12 agencies, are not shown here. They include the most recent record on file, 29 Dec 2025 from CONITEC (Brazil); its outcome is in the subscriber dataset. They link to 43 further source documents.
Related molecules
- vericiguat — divergent outcome (recommended vs not recommended) on a shared indication
- ivabradine — divergent outcome (recommended vs not recommended) on a shared indication
- empagliflozin — same ATC class A10B — Diabetes
- semaglutide — same ATC class A10B — Diabetes
- metformin / sitagliptin — same ATC class A10B — Diabetes
- liraglutide — same ATC class A10B — Diabetes
Coverage: 64 decisions for dapagliflozin from 12 agencies, 2012 to 2025. Data to 7 Sep 2026. ATC class A10B — Diabetes. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.